BacteriologyPoint-of-care testing for CXCL13 in Lyme neuroborreliosis
Section snippets
Funding
This work was supported by a grant from the Jane and Aatos Erkko Foundation. This work was financially supported by Reagena by providing the CXCL13 LFA tests.
Competing interests
J.H. is a part-time consultant for Reagena.
Authors' contributions
JH designed the study, performed chemokine analyses, analyzed the data, and drafted the manuscript. AP performed chemokine analyses, analyzed the data, and helped to draft the manuscript. JO analyzed the data and helped to draft the manuscript. All authors read and approved the final manuscript.
Acknowledgments
Tuula Rantasalo is acknowledged for performing chemokine analyses.
References (14)
- et al.
Lyme borreliosis
Lancet
(2012) - et al.
Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
BMC Neurol
(2013) - et al.
Borrelia burgdorferi–specific intrathecal antibody production in neuroborreliosis: a follow-up study
Neurology
(1993) - et al.
CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation
J Neuroinflammation
(2014) - et al.
Characteristics and clinical outcome of Lyme neuroborreliosis in a high endemic area, 1995–2014: a retrospective cohort study in Denmark
Clin Infect Dis
(2017) - et al.
Lyme neuroborreliosis—epidemiology, diagnosis and management
Nat Rev Neurol
(2015) - et al.
Lyme neuroborreliosis
Curr Opin Infect Dis
(2017)
Cited by (13)
CXCL13 in patients with facial palsy caused by varicella zoster virus and Borrelia burgdorferi: a comparative study
2020, Diagnostic Microbiology and Infectious DiseaseCitation Excerpt :As such, the added benefit of CXCL13 would be to avoid unnecessary antibiotic prescriptions and move focus to potential differential diagnoses. In a newly published study by Pietikäinen et al. (Pietikainen et al., 2018), the authors advocate for a new CXCL13 lateral flow assay, suitable for point-of-care testing. Such an assay could potentially widen the indication for CXCL13 testing, and have an impact on clinical practice.
Unconventional diagnostic tests for Lyme borreliosis: a systematic review
2020, Clinical Microbiology and InfectionCitation Excerpt :Four studies were finally retained: two meta-analyses [40,41], one retrospective controlled study [42] and one prospective uncontrolled study [43]. QUADAS-2 quality assessment demonstrated low risk of bias and low applicability concerns for both meta-analyses [40,41], unclear risk of bias and uncertainty regarding applicability for the retrospective controlled study [42], and high risk of bias and high concerns regarding applicability for the prospective uncontrolled study [43]. As demonstrated previously for Lyme neuroborreliosis, the CSF CXCL-13 concentration is high [40–44].
Utility of Nanobiosensors as a Point-of-Care Diagnostics for Neurological Disorders: From Bench to Bedside
2023, Nanobiosensors for Point-of-Care Medical DiagnosticsLyme borreliosis in children
2022, Cesko-Slovenska Pediatrie